RE:RE:RE:Earnings?@rothchikdish : Totally agree with respect to rec vs medicinal. The market has overhyped rec simply because they don't understand or buy in to the medicinal properties of CBD. The winners here though will be established pharma companies that have sofisticated labs to do the appropriate R&D and patent their findings. This is critical because the vast majority of prescribing doctors do so only on request at this point....they're just not convinced yet. But it's early and this will change in time. The novelty of rec will dissipate and margins will be eroded as it becomes commoditized. The opposite will be true for medicinal if the research proves to be conclusive. The pain industry is not going to roll over and give up the billions that opiates produce so this will take years. As to your comments on retrofits, I have to disagree....no matter how you slice it, it is less expensive than starting from scratch. You are forgetting that retrofit = time to market.....that cost alone is a huge opportunity cost for anyone building from scratch. By the time many of these low priced LPs get built out, much of the space could be redundant if in fact we end up with over capacity.
PaoloJr wrote: Rothchildish wrote: I've spoke with consultants in the field, retrofit will be cheaper on a capital basis, but will be more expensive on your operating expenses. Retrofits are not custom-made for the production of weed. I see huge potential in pharma's, and that is the reason why I invested in the first place, people only speak about recreationnal, but the real money will be made with pharmaceuticals. Earnings will be terrible, but it is to be expected, we might see a retracement though, so I'll keep some money on the side to buy some cheap shares.
i agree